This article is more than 5 years old. Information may no longer be current.

Presentation highlights link between HF guideline adherence, real-world outcomes

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

LOS ANGELES — In a presentation at the American Association of Heart Failure Nurses Annual Conference, Gregg C. Fonarow, MD, FACC, FAHA, Eliot Corday Professor of Cardiovascular Medicine and Science at the University of California at Los Angeles Division of Cardiology, stressed the importance of adherence to the most recent guidelines for HF treatment, and the impact that adherence can have on real-world patient outcomes.

The American College of Cardiology/American Heart Association Heart Failure Guidelines for the Management of HF, released in 2013, focused on the use of evidence-based therapies to improve outcomes among patients with HF.

Gregg C. Fonarow

“By helping us focus on those true evidence-based therapies, the guidelines allow us to improve the effectiveness of care and optimize patient outcomes, as well as favorably affect the overall cost and value of care by focusing resources on the most effective strategies,” Fonarow said.

He also noted that results from the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting study indicated that each 10% improvement in ACC/AHA HF guideline-recommended composite care was associated with a 13% reduced risk for mortality at 24 months.

“Evidence-based, guideline-directed diagnosis, evaluation and therapy should be the mainstay for all patients with HF,” Fonarow said. “Effective implementation of guideline-directed best quality care reduces mortality, improves quality of life and preserves health care resources. We need ongoing research to address some of the remaining questions we have regarding further improving clinical outcomes for this very important patient population.”

For more information:

Fonarow GC. Essentials of the Heart Failure Guidelines. Presented at: the American Association of Heart Failure Nurses Annual Conference; June 26-28, 2014; Los Angeles.

Disclosure: Fonarow is a consultant/scientific advisor for Gambro, Johnson & Johnson, Medtronic and Novartis.